filmov
tv
EMPA-Kidney Results
Показать описание
Janani Rangaswami, MD interviews David Preiss, PhD about the results of EMPA-Kidney. #AHA22
0:01:35
EMPA-KIDNEY: meta-analysis results
0:01:52
EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths
0:01:14
EMPA-KIDNEY results November 2022
0:03:21
EMPA CKD - 3 min trial summary
1:06:22
EMPA KIDNEY results: Flozins for all CKD with Dr Will Herrington
0:05:15
EMPA-KIDNEY
0:03:07
EMPA KIDNEY FINAL
0:57:22
Emerging data from EMPA-KIDNEY study
0:03:06
Empagliflozin: A Game Changer for Chronic Kidney Disease
0:08:58
EMPA-KIDNEY
0:02:33
EMPA-KIDNEY: Introduction to the trial
0:07:23
Empa Kidney Trial
1:08:25
Webinar: Overview of high impact clinical trials: EMPA-Kidney and STOP-ACEi
0:05:38
ESC TV On the Road - #AHA22 - DCP and EMPA-KIDNEY trials
0:02:11
Empagliflozin decreases risk of kidney function decline in T2D: EMPA-REG OUTCOME
0:48:26
Empa-kidney: Empagliflozin in patients with chronic kidney disease - Dr. Julian Ocampo
1:24:14
Empagliflozin & Kidney Disease: The EMPA-KIDNEY STUDY (LIVE)
0:02:41
FDA Approves Empagliflozin for Reducing Kidney Disease Progression in CKD Patients
0:00:54
Empagliflozin: Protecting Kidneys Even After Stopping?
1:04:53
Update SGLT-2 Hemmer - EMPA-Kidney & KDIGO - Prof. Christoph Wanner und Prof. Christoph Maack
0:48:38
KDIGO Leitlinien DM & CKD / EMPA-Kidney - Prof. Wanner
0:09:06
SGLT2 Inhibitors in Chronic Kidney Disease
0:26:36
Professor Christoph Wanner - Renoprotective effects of SGLT2 inhibitors
0:10:25
Estudio EMPA-KIDNEY
Комментарии